Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy

被引:8
|
作者
Tillman, Joanne [1 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, Intens Care Unit, London SE1 7EH, England
关键词
Adult intensive care unit; Citrate; Haemofiltration; Heparin; Renal failure; CONTINUOUS VENOVENOUS HEMOFILTRATION; REGIONAL CITRATE; HEMODIALYSIS; RISK;
D O I
10.1111/j.1478-5153.2009.00339.x
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Background: Continuous renal replacement therapy (CRRT) is commonly used in the care of critically ill patients (Gabutti et al., 2002). Critical illness increases the likelihood to both coagulation and bleeding, making anticoagulation for CRRT problematic. Aims: This mini-review aims to examine the evidence that compares the use of systemic heparin and regional citrate as forms of anticoagulation for CRRT in critically ill patients. The primary outcome of interest was haemofilter circuit survival, and the secondary outcome was reduced risk of bleeding. Search strategy: A systematic literature search was undertaken to identify all studies comparing these drugs. The Cochrane Library, Medline and Embase databases were searched. Eighty-nine articles were found. Included studies were randomized controlled trials (RCTs), which used a target population of critically ill adults. Studies were excluded if they had not been written in English and if they were not available through King's College London. After applying the inclusion and exclusion criteria, three RCTs comparing the use of systemic heparin and regional citrate were included in the review. Results: Two studies showed significant differences in circuit survival time, with citrate prolonging survival time. All studies showed an increased risk of bleeding in the heparin group, resulting in a higher rate of transfusion while heparin was being used. Conclusions: The studies examined lacked reference to the power of the studies and strength in the presentation of the results. Because of the lack of reliability in the studies, it would be suggested that further research is needed on this topic in order to produce rigorous high-quality reviews with limited bias. The use of citrate, as with all treatments in clinical practice, should be used with caution and assessed on an individual patient basis. Reviewing this evidence helps to gain an insight into different treatment options available, identifying some of the risks and benefits.
引用
收藏
页码:191 / 199
页数:9
相关论文
共 50 条
  • [21] Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials
    Liu, Chao
    Mao, Zhi
    Kang, Hongjun
    Hu, Jie
    Zhou, Feihu
    CRITICAL CARE, 2016, 20
  • [22] Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
    Heleen M Oudemans-van Straaten
    John A Kellum
    Rinaldo Bellomo
    Critical Care, 15
  • [23] Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
    Oudemans-van Straaten, Heleen M.
    Kellum, John A.
    Bellomo, Rinaldo
    CRITICAL CARE, 2011, 15 (01):
  • [24] Anticoagulation in Continuous Renal Replacement Therapy: Citrate Appears to Be Superior to Heparin!
    Bunchman, Timothy E.
    PEDIATRIC CRITICAL CARE MEDICINE, 2016, 17 (09) : 894 - 895
  • [25] Meta-analysis of regional citrate versus heparin anticoagulation for continuous renal replacement therapy
    Volbeda, Meint
    Franssen, Casper F. M.
    THERAPEUTIC APHERESIS AND DIALYSIS, 2024, 28 (03) : 475 - 476
  • [26] PREDICTIVE FACTORS FOR ACCUMULATION OF CITRATE DURING CONTINUOUS RENAL REPLACEMENT THERAPY AND ANTICOAGULATION WITH CITRATE IN CRITICALLY ILL PATIENTS WITH SEVERE LIVER DYSFUNCTION
    Stadler, Theresa
    Raddatz, Alexander
    Poppleton, Aaron
    Hubner, Wakiko
    Fliser, Danilo
    Klingele, Matthias
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 356 - 357
  • [27] Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
    Matthias Klingele
    Theresa Stadler
    Danilo Fliser
    Timo Speer
    Heinrich V. Groesdonk
    Alexander Raddatz
    Critical Care, 21
  • [28] Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
    Klingele, Matthias
    Stadler, Theresa
    Fliser, Danilo
    Speer, Timo
    Groesdonk, Heinrich V.
    Raddatz, Alexander
    CRITICAL CARE, 2017, 21
  • [29] Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation
    Khadzhynov, Dmytro
    Dahlinger, Annette
    Schelter, Christin
    Peters, Harm
    Kindgen-Milles, Detlef
    Budde, Klemens
    Lehner, Lukas Johannes
    Halleck, Fabian
    Staeck, Oliver
    Slowinski, Torsten
    CRITICAL CARE MEDICINE, 2017, 45 (09) : E941 - E946
  • [30] PREDICTIVE FACTORS FOR ACCUMULATION OF CITRATE DURING CONTINUOUS RENAL REPLACEMENT THERAPY AND ANTICOAGULATION WITH CITRATE IN CRITICALLY ILL PATIENTS WITH SEVERE LIVER DYSFUNCTION
    Stadler, Theresa
    Raddatz, Alexander
    Hubner, Wakiko
    Poppleton, Aaron
    Fliser, Danilo
    Klingele, Matthias
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 104 - 104